Core Viewpoint - Shanghai Cathay Biotech Co., Ltd. is conducting a private placement of A-shares, which will significantly increase the control of its major shareholder, Shanghai Yaoxiu, from 20.00% to 35.29% after the issuance, thereby consolidating the actual control of the company by Xiucai Liu's family [2][20]. Group 1: Issuance Details - The total number of shares to be issued is 137,911,755, which does not exceed 30% of the total share capital before the issuance [12][19]. - The issuance price is set at 42.97 CNY per share, adjusted from an initial price of 43.34 CNY due to previous dividend distributions [14][13]. - The total funds raised from this issuance amount to 5,926,068,112.35 CNY, with a net amount of 5,914,724,993.63 CNY after deducting issuance costs [12][26]. Group 2: Shareholder Structure - Post-issuance, the actual control of the company by Xiucai Liu's family and controlled enterprises will increase to 44.04% [20]. - The major shareholder, Shanghai Yaoxiu, will have its shareholding increased significantly, enhancing its control over the company [2][20]. - The shareholding structure complies with the listing conditions as per the relevant regulations [2][20]. Group 3: Lock-up Period and Trading - The shares issued will be subject to a lock-up period of 60 months, during which they cannot be transferred [15][27]. - After the lock-up period, the shares will be listed and traded on the Shanghai Stock Exchange's Sci-Tech Innovation Board [27]. Group 4: Company Overview - Shanghai Cathay Biotech Co., Ltd. specializes in the research, production, and sales of new bio-based materials, primarily focusing on bio-based long-chain dicarboxylic acids and bio-based polyamide products [6][7]. - The company has established long-term partnerships with international firms such as DuPont and Evonik, leveraging its leading position in the global market for bio-based long-chain dicarboxylic acids [7][20].

36氪Pro . 36氪旗下官方账号。深度、前瞻，为1%的人捕捉商业先机。 以下文章来源于36氪Pro ，作者海若镜 向海外头部聚酯企业 交付了吨级高纯FDCA订单。 文 ｜ 海若镜 来源｜ 36氪Pro（ID：krkrpro） 凭借优异的阻隔性能和良好的机械性能，FDCA材料在食品药品包装、纺织等领域都有巨大应用潜力。在食品包装方面，PET制作的食品包装袋、包装盒、 饮料瓶等，能够有效延长食品的保质期，保持食品的新鲜度和口感。在药品包装方面，FDCA材料的高阻隔性能可以防止药品受潮、氧化和变质，确保药品 的质量和安全性。在纺织品方面，FDCA合成的聚酯纤维，具有良好的强度、耐磨性和染色性能，特别在运动和户外服装方面，可以提供更好的透气和吸湿 排汗性能等。 当前，中科国生正在开发多种应用场景，为了快速响应市场需求，其搭建了"柔性研发和生产体系"，以缩短呋喃生物基材料从实验室开发到商业化落地的周 期。 封面来源 ｜ IC photo 36氪获悉，"中科国生"近日获两亿元A+轮融资，由中信金石、普华资本领投，赟汇资本、杭州资本跟投，老股东君联资本、五源资本、余杭国投继续加 注。据公司介绍：本轮融资将用于位于江苏泰 ...